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Abstract
Malignant growth of small-cell lung carcinoma is promoted by various neuroendocrine autocrine/
paracrine loops. Therefore, to interfere with this mitogenic process, it is crucial to elucidate the
mechanisms involved. It is known that the oxytocin (OT) and vasopressin (VP) genes, normally
transcriptionally restricted in their expression, are activated in small-cell lung cancer (SCLC),
concomitantly with expression of their receptors (OTR, V1aR, V1bR/V3R and V2R). The aim of the
present study was to characterize, in concentrations close to physiological and pharmacological
conditions, intracellular signalling events triggered by OT and VP binding to their specific receptors in
SCLC cells and to identify factors mediating OT- and VP-induced mitogenic effects on SCLC. Known
agonists for OTR ([Thr4,Gly7]OT) and V1aR (F180), in addition to OT and VP, were able to elicit
increases in cytosolic Ca2+ levels and this effect could be blocked using an OTR antagonist (OVTA) or
a V1aR antagonist (SR49059) respectively. There was no activation of the cAMP pathway detected
after VP, dDAVP (a V2R agonist), or OT treatment. Stimulation of SCLC cells with OT and VP led to an
increase of extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, maximal at 5 min, and the
subsequent phosphorylation of its downstream target p90 ribosomal S6 kinase (p90RSK). Pre-
incubation with OVTA and SR49059, and with inhibitors of phospholipase C (PLC), protein kinase C
(PKC), mitogen-activated protein kinase/ERK kinase (MEK) 1/2 and a Ca2+ chelator significantly
reduced OT- and VP-induced ERK1/2 phosphorylations. OVTA, SR49059 as well as MEK1/2 and PKC
inhibitors also downregulated OT- and VP-induced p90RSK phosphorylation. In [3H]thymidine-uptake
experiments, we subsequently observed that PLC, Ca2+, PKC and ERK1/2 are absolutely required for
the OT- and VP-stimulated SCLC cellular growth process. In conclusion, the results presented here
indicate that OT- and VP-induced mitogenic effects on SCLC are respectively mediated by OTR and
V1aR signalling and that this mitogenic signalling passes through the phosphorylation of ERK1/2 and
p90RSK in a PLC-, Ca2+-, PKC- and MEK1/2-dependent pathway.
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Introduction
As a basic component of oncogenesis, neuroendocrine
tumour cells usually develop very potent autocrine/
paracrine signalling pathways that play a crucial part in
the dysregulation of cellular growth (Hanahan&Weinberg
2000, Zochbauer-Muller et al. 2002). Among such auto-
crine/paracrine loops, the neurohypophysial peptide sys-
tem is implicated in the pathogenesis of an increasing
number of cancers and particularly in small-cell lung
carcinoma (SCLC) (North 2000, Cassoni et al. 2001).
Ligands of this system include the neurohypophysial
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hormones oxytocin (OT) and vasopressin (VP). There is
only one known receptor for OT, OTR, and three main
receptors for VP, V1aR, V1bR/V3R and V2R, by which
respective hormones exert their physiological actions
(Birnbaumer et al. 1992, Kimura et al. 1992, de Keyzer et
al. 1994, Sugimoto et al. 1994, Thibonnier et al. 1994, Jard
1998). Tumour production, secretion of VP and its
mitogenic action on SCLC cellular growth are well
documented (Woll & Rozengurt 1989a, Sethi & Rozengurt
1991, Friedmann et al. 1994, North 2000, Rozengurt 2002).
Moreover, it is now established that these tumours also
express and secrete OT (North et al. 1993, Pe´queux et al.
2002). In SCLC, OT and VP have been shown to induce a
dose-dependent (from 1nM) and time-persistent increase
of tumour cell proliferation. This mitogenic effect of OT
was completely abolished by the OTR antagonist
ðdðCH2Þ15 , TyrðMeÞ2, Thr4, Orn8, Tyr9-NH2Þ-vasotocin
(OVTA) which when used alone induces a reduction of
SCLC cellular growth (Pe´queux et al. 2002). However, the
subsequent signalling pathways involved in this OT-related
mitogenic effect have not been fully investigated.
The biological effects of neuropeptides result from the
activation of complex intracellular networks rather than
linear signalling cascades (Heasley 2001, Rozengurt 2002).
The OTR, V1aR, V1bR/V3R and V2R all belong to the
superfamily of G-protein-coupled receptors (GPCRs),
which are structurally characterized by seven transmem-
brane domains. These GPCRs form constitutive homo-
and heterodimers, although no differences in pharmacolo-
gical and signalling properties have been shown as a result
of these interactions (Terrillon et al. 2003, Devost & Zingg
2004). The OTR, as well as the V1aR and V1bR/V3R,
mediate phosphatidylinositol hydrolysis and cytosolic
Ca2+ increase, whereas V2R is coupled to adenylate
cyclase and the second messenger cAMP (Barberis et al.
1998). In certain cell types expressing OTR or V1aR, OT
and VP can induce phosphorylation and activation of
mitogen-activated protein kinases (MAPKs; Ohmichi et al.
1995, Chiu et al. 2002, Zingg & Laporte 2003). All known
neurohypophysial peptide GPCRs are expressed in SCLC
(Friedmann et al. 1994, North et al. 1997, North et al.
1998a, 1998b, Pe´queux et al. 2002). Moreover, all these
receptors have the ability to bind VP and/or OT with
varying afﬁnity. Thus both ligands are capable of initiating
signalling cascades mediated by either receptor (Barberis et
al. 1999). Altogether, these data suggest that the neurohy-
pophysial hormone system displays a high degree of
complexity in the tumour modulation of SCLC cellular
growth. Moreover, the oxytocinergic system (OT and
OTR) is implicated in the growth modulation of various
neoplastic cells where it may inhibit or stimulate cell
proliferation. These discordant effects have the potential to
be a consequence of the activation of different signal
transduction pathways which result in increased cytosolic
Ca2+ or the formation of cAMP (Bussolati & Cassoni
2001, Cassoni et al. 2001, Cassoni et al. 2002). Addition-
ally, the activation of particular signalling intermediates by
the OTR depends on its localization inside or outside
caveolin-enriched domains resulting in a mitogenic or anti-
mitogenic response to OT stimulation, respectively (Guzzi
et al. 2002, Rimoldi et al. 2003).
These data emphasize the crucial part played by
transduction signalling in mediation of neuropeptide
effects. Therefore, in order to clarify the mechanisms
leading to SCLC cellular growth dysregulation, we
investigated the OT- and VP-induced mitogenic responses
and the activation of signal transduction mediators in
H345 and H146 SCLC cell lines. Speciﬁc agonists and
antagonists of the OT and VP GPCRs were employed to
further dissect ligand-mediated receptor activation
involved in SCLC cellular growth. In order to extrapolate
our in vitro ﬁndings to relevant physiological and
pharmacological conditions, we adhered strictly to the
concentrations of OT and VP that would be observed in
vivo. The maintenance of this appropriate concentration is
crucial for delineating the speciﬁcity of ligand binding (i.e.
OT and VP) to their appropriate receptors. These results
show that the OT- and VP-induced mitogenic effects on
SCLC are mediated largely by the OTR and the V1aR,
respectively, and that their activation leads to increases in
cytosolic Ca2+, but not in production of cAMP. OT and
VP stimulation also results in the increased phosphoryla-
tion of extracellular signal-regulated kinases (ERKs) 1
(p44MAPK) and 2 (p42MAPK) and of p90 ribosomal S6
kinases (p90RSKs). These phosphorylations are mediated
by phospholipase C (PLC)-, Ca2+-, protein kinase C
(PKC)- and MAPK/ERK kinases (MEK1 and MEK2)-
dependent pathways.
Materials and methods
Reagents and cell culture
Dulbecco’s PBS (DPBS), fetal calf serum and RPMI 1640
were purchased from Cambrex (Verviers, Belgium); OT
and VP originated from Calbiochem (VWR, Leuven,
Belgium). Desmopressin or (deamino-Cys1, D-Arg8)VP
(dDAVP; a V2R agonist; Zaoral et al. 1967) and OVTA
(an OTR antagonist; Manning et al. 1989) were obtained
from Bachem (Bubendorf, Switzerland). F180 (a V1aR
agonist; Aurell et al. 1990, Andres et al. 2002) was
provided kindly by P. Riviere (Ferring Research,
San Diego, CA, USA), [Thr4, Gly7]OT (an OTR agonist;
Lowbridge et al. 1977) by M. Manning (Medical College
of Ohio, Toledo, OH, USA) and SR49059 (a
V1aR antagonist; Serradeil-Le Gal et al. 1993) by
C. Serradeil-Le Gal (Sanoﬁ Recherche, Montpellier,
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France). Indo-1-AM (where AM is acetoxymethyl ester),
EGTA-AM and ionomycin (4-bromo A-23187) were
purchased from Molecular Probes (Eugene, OR, USA).
Insulin–transferin–sodium selenite (ITS) solution (I-
1884), BSA (fraction V, A-4503), forskolin, isobutyl-
methylxanthine (a phosphodiesterase inhibitor) and glu-
cose were obtained from Sigma. CompleteTM protease-
inhibitor cocktail tablets were from Roche, [3H]thymidine
was from Amersham Pharmacia Biotech and scintillation
liquid from Perkin Elmer (Courtaboeuf, France).
The origins of the antibodies were as follows:
polyclonal anti-b-actin (ab8227) was from Abcam (Cam-
bridge, UK), and polyclonal anti-p42/44MAPK (ERK1/
2; #9102), polyclonal anti-phospho-p42/44MAPK (ERK1/
2; #9101), polyclonal anti-phospho-p90RSK (#9344) and
anti-rabbit IgG horseradish peroxidase-linked (#7074)
antibodies were from Cell Signaling Technology (Beverly,
MA, USA). U73122 (a PLC inhibitor), GF109203X (a
PKC inhibitor) and BAPTA-AM (bis-(o-aminophenoxy)-
ethane-N, N, N0, N0-tetra-acetic acid AM; a Ca2+
chelator) were obtained from BIOMOL Research
Laboratories (Plymouth Meeting, PA, USA) and U0126
(a MEK1/2 inhibitor; #9903) was from Cell Signaling
Technology.
The classical SCLC cell lines NCI H345 and NCI
H146 were purchased from American Type Culture
Collection (Manassas, VA, USA). Cells were cultured in
a humidiﬁed atmosphere of 5% CO2 and 95% air at
37 8C, according to American Type Culture Collection
recommended guidelines.
Flow-cytometric analysis of Ca2+ kinetics
H345 cells routinely cultured were washed twice with
DPBS. Cells ð3 106 ; cells=mlÞ were loaded by incubating
them for 45min at 378C in serum-freemedium (RPMI 1640
+ ITS 1%) containing 5 mM indo-1-AM. After two washes
with DPBS, cells were suspended at 1 105 cells=ml in a
Ca2+ buffer made of DPBS containing CaCl2 (1mM),
glucose (1mg/ml) and BSA (0.1%). Loaded cells were kept
at room temperature until ﬂow analysis was performed on
a Facstar plus ﬂow cytometer (BectonDickinson, Franklin
Lakes, NJ, USA). Prior to analysis, loaded cells (900ml)
were placed at 378C for 2–5min. Fluorescence records of
each sample were measured over approximately 4 min, at
an excitation wavelength of 356 nm and emission wave-
lengths of 405 nm (Ca2+-bound indo-1-AM) and 485 nm
(free indo-1-AM). The various peptide ligands being tested
(Table 1) were administered as 100 ml volumes in 1mM
Ca2+ buffer to cell samples after 30 s of baseline recording.
Proper loading of the cells with indo-1-AM was conﬁrmed
(approximately 80–90% of responding cells) by stimula-
tion with ionomycin (4-bromo A-23187; 10mM), which
induces Ca2+ inﬂux from the extracellular medium.
Incubation of the cells with EGTA-AM (0.01mg/ml)
5min prior to ﬂow measurement, as well as administration
of Ca2+ buffer without ligand, were used as suitable
negative controls. Receptor activity was speciﬁcally
blocked by pre-incubating the cells with antagonists of
the OTR or V1aR for 15min at 378C prior to measuring
their baseline and agonist-stimulated cytosolic Ca2+ levels
by ﬂow cytometry. The agonists tested were OT (1 nM), VP
(1 nM), F180 (V1aR agonist; 20 nM) and [Thr4, Gly7]OT
(OTR agonist; 5 nM). The antagonists were SR49059
(V1aR antagonist; 10 nM) and OVTA (OTR antagonist;
0.5 nM). Data were analysed using Flowjo 3.4 software
(Tree Star, Ashland, OR, USA) and plotted as the ratio
405 nm/485 nm expressed as the percentage of responding
cells over a threshold of 200 (mean ratio 405 nm/485 nm)
against time (s).
cAMP kinetics
Prior to cAMPanalysis, H345 andH146 cells were cultured
overnight in serum-freemedium (RPMI 1640+BSA 0.1%
+ ITS 1%) at a density of 1 106 cells/ml under normal
conditions. The cells were then treated for periods from 0 to
60min at 378C with OT, VP or dDAVP (V2R agonist) in
the presence of isobutylmethylxanthine (50 mM). Treat-
ment with the adenylate cyclase activator forskolin was
Table 1 Neurohypophysial peptide agonist and antagonist Kd values in humans
Kd (nM)
Ligands V1aR V1bR/V3R V2R OTR
VP 1.0 0.7 3.3 1.6
F180 11.7 2100 > 10 000 520
dVAVP
(1-deamino, 8-D-arginine)VP 21 22 2.7 203
SR49059 0.9 129 119 33
OT 146 1160 1540 0.8
[Thr4,Gly7]OT 78.8 – – 6.6
OVTA 3.9 10 229 929 0.2
Dissociation constant (Kd) values are taken from Barberis et al. (1999) and Andres et al. (2002)
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performed as a positive control. OT, VP and dDAVP were
tested at concentrations of 1 nM, 10 nM, 100 nM and 1mM
and forskolin was used at 1 and 10 mM. After the
appropriate time, the reactions were stopped by centrifu-
gation (250 g, 48C, 5min). Supernatants were discarded
and the pellets were washed with DPBS (2ml, 48C). After
centrifugation, the cell pellets were lysed in 1ml ethanol
(95%)/HCl (0.01M) at 48C, and then vortexed three times
for 20 s. Samples were centrifuged (13 600 g, 48C, 15min)
and the supernatants (900ml) were collected in 1.5ml tubes,
lyophilized and stored at 208C until assayed. The cAMP
content was determined using a RIA kit (RPA 509;
Biotrak, Amersham Biosciences).
Preparation of cell lysates and Western blot
kinase phosphorylation analysis
H345 and H146 cells in stock culture were washed in
DPBS and seeded into 12-well plates in serum-free
medium (RPMI 1640 + BSA 1%) at a density of
3 106 cells/well, and cultured overnight. Cells were pre-
incubated in RPMI 1640 alone (control) or containing
U73122 (PLC inhibitor; 2.5 mM), BAPTA-AM (Ca2+
chelator; 20 mM), GF109203X (PKC inhibitor; 20 mM) or
U0126 (MEK1/2 inhibitor; 10mM) for 45min, or they
were pre-incubated in RPMI 1640 containing OVTA
(OTR antagonist; 0.5 nM) or SR49059 (V1aR antagonist;
10 nM) for 15min. Then, cells were stimulated with OT or
VP at a ﬁnal concentration of 1 nM for the indicated
period of time (basal control is unstimulated). Reactions
were stopped by addition of ice-cold DPBS. Ice-cold
DPBS and lysing buffer (20mM HEPES, 150mM NaCl,
10% glycerol, 0.5% Triton X-100, 1mM dithiothreitol,
1mM Na3VO4, 25mM b-glycerophosphate, 1mM NaF
and 1 tablet/50ml CompleteTM) were used to wash the
cells twice and extract their protein. After centrifugation
(18 000 g, 15min, 48C) supernatants were isolated and
aliquots were assayed for protein content using the
Bradford protein assay (BioRad). Cell lysates were
conserved at 208C until Western blot procedure.
Cellular proteins (20mg) were separated by 10% SDS-
PAGE and Western transferred on to polyvinylidene
diﬂuoride (PVDF; ImmobilonTM-P; Millipore, Bedford,
MA, USA) membranes. After activation in methanol
(100%), blots were incubated for 1 h at room temperature,
in TBS-T (20 mM Tris/HCl, 140mM NaCl and 0.2%
Tween 20, pH7.6) containing 5% powdered skimmed milk
(Gloria1; Nestle´, Switzerland; TBS-T/milk). After wash-
ing, membranes were incubated overnight at 48C with the
appropriate primary polyclonal antibody (see legends of
Figs 3 and 4 for speciﬁc antibodies) at a concentration
recommended by the manufacturer, in TBS-T containing
5% BSA. After washing, the membranes were incubated
for 1 h at room temperature with the horseradish perox-
idase-linked anti-rabbit IgG diluted in TBS-T/milk,
washed again, and the immunocomplexes visualized by
chemiluminescence reaction (ECLTM Western blotting
Detection Reagents; Amersham Biosciences). For signal
quantiﬁcation, membranes were densitometrically scanned
(Gs-700; BioRad) and analyzed with Quantity One 4.2.1
software (BioRad). Quantiﬁcation of phosphorylated
protein forms was carried out by expressing their intensity
relatively to the intensity generated by b-actin or ERK1/2
immunoblotting and as a ratio of basal activation.
Cell proliferation
Cellular growth and toxicity were evaluated for the same
experiment by respective measurement of [3H]thymidine
incorporation into DNA and of lactate dehydrogenase
(LDH) release in culture supernatants using a standard
chemical procedure (Roche). H345 and H146 cells in
stock culture were washed in DPBS and replated in T
culture ﬂasks (25 cm2; VWR, Belgium) in RPMI 1640
added with 5% charcoal-treated fetal calf serum (charcoal
treatment discards small molecules and proteins such as
OT and VP) at an initial density of 1 105 cells/ml and
cultured overnight. Then, RPMI 1640 (basal control), OT
or VP were added in culture medium at ﬁnal concentra-
tion of 1 nM. After 72 h of culture with hormone or
solvent, U73122, BAPTA-AM, GF109203X, U0126 or
DMSO (1/2000) diluted in RPMI 1640 (control) were
added to culture medium at ﬁnal concentrations ranging
from 2.5 to 10mM. After 30min and 1, 2, 4, 24, 48 and
72 h of culture with these inhibitors or solvent, 1ml cell
suspension was taken and distributed in triplicate on 96-
well plates (200 ml/well) for [3H]thymidine incorporation.
The remaining cell-suspension fraction was centrifuged
(250 g, 208C, 10min), and 200 ml supernatant was mixed
with CompleteTM protease-inhibitor cocktail and 50%
glycerol (v/v) and stored at -208C till LDH assay.
LDH baseline and positive control were respectively
LDH measures in culture medium or when 1 ml cell
suspension was lysed with RPMI 1640 with 2% Triton X-
100. On 96-well plates, [3H]thymidine (25 ml, 11.5 mCi/ml)
was added and plates were incubated for 4 h in a
humidiﬁed atmosphere of 5% CO2 and 95% air at
378C. Cellular DNA was harvested from the cells using a
Titertek cell harvester (Flow Laboratories, McLean, VA,
USA). One-minute sample counts were obtained in a
Beckman liquid scintillation counter (Beckman, Full-
erton, CA, USA).
Statistical analyses
Variations in [3H]thymidine uptake were analyzed statis-
tically with GraphPad PrismTM software (GraphPad
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Software, San Diego, CA, USA), using ANOVA followed
by Student–Newman–Keuls test.
Results
OT- and VP-induced Ca2+ kinetics
In order to assess whether OT, in addition to VP, could
initiate in SCLC, under ligand concentrations within the
range in vivo, the inositol-mediated pathway usually
associated with OTR, V1aR and V1bR/V3R, changes in
H345 cytosolic Ca2+ level were measured by ﬂow
cytometry. There was a 40% increase in the cytosolic
Ca2+ levels observed in response to OT or VP at 1 nM
(Fig. 1). Speciﬁc activation of the OTR or the V1aR
located in the H345 cell membrane was tested using
receptor agonists at selective concentrations (see Table 1).
Stimulation with [Thr4, Gly7]OT (OTR agonist) at 5 nM
or with F180 (V1aR agonist) at 20 nM resulted in a clear
increase (35%) in cytosolic Ca2+ (Fig. 1). Depending on
their concentrations, OT and VP can bind each of the
neurohypophysial peptide GPCRs (see Table 1). To
identify which receptor(s) mediate the OT- or VP-induced
increase in cytosolic Ca2+, cells were exposed to OTR
antagonist (OVTA) or V1aR antagonist (SR49059) at
concentrations (0.5 and 10 nM respectively) that selec-
tively block those receptors (see Table 1). Cell pre-
incubation with antagonists was followed by stimulation
Figure 1 Effect of OT and VP on Ca2+ kinetics with or without antagonist pre-incubation. For antagonist pre-incubation, indo-1-AM-
loaded H345 cells were exposed to the V1aR antagonists SR49059 (10 nM), or the OTR antagonist OVTA (0.5 nM) for 15 min at
378C. Then, changes in cytosolic free calcium were measured using flow-cytometric analysis to determine the 405/485 nM
emissions ratio over a 200-s period. After approximately 30 s of baseline, samples were injected with OT (1 nM), OTR agonist
[Thr4,Gly7]OT (5 nM), VP (1 nM) or V1aR agonist F180 (20 nM). Data are expressed as the percentage of responding cells over a
threshold of 200 (mean ratio 405 nM/485 nM) against time (s). Kinetics shown are representative of two independent experiments.
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with OT, VP, [Thr4, Gly7]OT or F180 at pharmacological
concentrations. Pre-incubation with SR49059 almost
completely blocked the increases of cytosolic Ca2+
induced by VP at 1 nM or F180 at 20 nM, while OT at
1 nM and [Thr4, Gly7]OT at 5 nM were still able to elicit
increases in the cytosolic Ca2+ levels. Pre-incubation with
OVTA was able to block the OT-induced but not the VP-
induced increase in cytosolic Ca2+ (Fig. 1).
cAMP kinetics
To discern whether adenylate cyclase-mediated signal
transduction, generally associated with the V2R response,
could be initiated in SCLC cells after stimulation with OT
or VP, measurements of intracellular cAMP kinetics were
performed on H345 and H146 cells. When the cells were
incubated with VP, OT or the V2R agonist dDAVP, each
at 1 nM, there was no increase observed in the intra-
cellular cAMP levels, even after 60min exposure (Fig.
2A). Various incubation times (15–60min) and ligand
concentrations (1 nM to 1mM) were tested; however, there
were no signiﬁcant changes in either SCLC cell line in the
intracellular levels of cAMP detected. The results
obtained from H345 and H146 cells after 30min incuba-
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Figure 2 Effect of VP, dDAVP and OT on cAMP kinetics. (A) H345 or H146 cells were incubated with VP (*), dDAVP (*, V2R
agonist) or OT ð~Þ at a ligand concentration of 1 nM, or with forskolin (&, 1 mM, or&, 10mM) used as a positive control, for 15, 30,
45 or 60 min. The amount of cAMP is expressed as pmol/106 cells against time (min) (n ¼ 3; mean S.D.). (B) H345 or H146 cells
were incubated with VP (*), dDAVP (*, V2R agonist) or OT (~) at agonist concentrations of 1, 10, 100 or 1000 nM for 30 min. The
amount of cAMP is expressed as pmol/106 cells against log ligand concentration (nM) (n ¼ 3; mean S.D.). Measurements were
obtained by RIA on proteins extracted from H345 or H146 cytoplasm. Basal cAMP levels were determined at time 0, prior to
exposure to agonist.
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OT- and VP-induced ERK1/2 phosphorylations
and pathway
MAPKs, and particularly ERK1/2, two highly conserved
serine/threonine kinases activated via protein phosphor-
ylation cascades, have been shown to be associated in
proliferation processes of various cell types (Johnson &
Lapadat 2002). Moreover, phosphorylation of ERK1/2 is
implicated in the growth of cells transfected with the OTR
(Rimoldi et al. 2003) or the V1aR (Thibonnier et al. 2000).
Therefore, SCLC H345 and H146 cells were treated with
either OT or VP at 1 nM and cell lysates were analysed for
ERK1/2 phosphorylation. After 5 min treatment, OT and
VP induced comparable increases of ERK1/2 phosphor-
ylation in both cell lines. There was a 3-fold ðn ¼ 16Þ and
a 2.5-fold ðn ¼ 22Þ average OT- or VP-induced increase in
ERK1/2 phosphorylation measured in H345 and H146
cells respectively, compared to the baseline levels of
phospho-ERK1/2, and these increases started to decline
after 15min (Fig. 3A). Indeed, it must be noted that an
ERK1/2 basal level of activation was usually observed in
both SCLC cell lines (Fig. 3). Knowing that these cells
secrete endogenous OT and VP (Pe´queux et al. 2002), the
effect of antagonists of these neuropeptides was evaluated
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Figure 3 Effect of OT and VP on ERK1/2 phosphorylation with or without pre-incubation with specific signal transduction inhibitors.
Proteins were extracted and separated by 10% SDS-PAGE and Western blot analysis was performed using a polyclonal anti-
phospho-ERK1/2 antibody. Cells were incubated (þ) or not () with OT (1 nM) or VP (1 nM) for 3, 5 and 15 min. A polyclonal anti-
ERK1/2 antibody was used to normalize loading (A). Cells were pre-incubated (þ) with OTR antagonist OVTA (0.5 nM) (B), V1aR
antagonist SR49059 (10 nM) (C), or with solvent () for 15 min. Cells were pre-incubated (þ) with PLC inhibitor U73122 (2.5mM)
(D), Ca2+ chelator BAPTA-AM (20mM) (E), PKC inhibitor GF109203X (20mM) (F), MEK1/2 inhibitor U0126 (10mM) (G), or with
solvent () for 45 min. Then, after these pre-incubations, cells were stimulated (þ) or not () with OT (1 nM) or VP (1 nM) for 5 min.
A polyclonal anti-b-actin antibody was used to normalize loading. Western blots shown are representative of at least three
independent experiments, each performed on H345 and H146 cells.
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on the ERK1/2 basal level of phosphorylation. In both
SCLC cell lines studied, the OTR antagonist OVTA and
the V1aR antagonist SR49059, used at selective concen-
trations of 0.5 and 10 nM respectively, reduced the basal
level of phosphorylated ERK1/2 (Table 2, Fig. 3B and C).
These antagonists were also used to check the speciﬁcity
of ERK1/2 phosphorylation increases induced by exo-
genous OT and VP. In H345 and H146 cells, treatment
with the OTR antagonist OVTA prevented OT-induced
ERK1/2 phosphorylation, while it presented a minor
effect on the VP-induced ERK1/2 phosphorylation (Table
3, Fig. 3B). Similarly, the effect of the V1aR antagonist
SR49059 prevented VP-induced ERK1/2 phosphoryla-
tion, while its effect on the OT-induced ERK1/2
phosphorylation remained weaker (Table 3, Fig. 3C).
In order to identify the upstream mediators involved
in the observed ERK1/2 phosphorylations, speciﬁc
pharmacological inhibitors of signal transduction were
examined for their effect on OT- and VP-induced ERK1/2
phosphorylation (Fig. 3, Table 3). OT and VP increase
cytosolic Ca2+, and this pathway is activated when OTR
or V1aR are coupled to Gaq/11; thus contributions of
PLC and Ca2+ to the mediation of ERK1/2 phosphor-
ylation were examined. Pre-incubation of H345 and H146
cells with the PLC inhibitor U73122 (2.5 mM; Fig. 3D)
and the Ca2+ chelator BAPTA-AM (20 mM; Fig. 3E)
reduced OT- and VP-induced ERK1/2 phosphorylation in
a similar manner in both cell lines (Table 3). OT- and VP-
induced ERK 1/2 phosphorylation was downregulated by
the PKC inhibitor GF109203X (20mM) similarly in both
SCLC cells (Table 3, Fig. 3F). Moreover, these phosphor-
ylations were almost completely blocked by the MEK1/2
inhibitor U0126 (10 mM), conﬁrming their speciﬁcity
(Table 3, Fig. 3G).
OT- and VP-induced p90RSK phosphorylation
A downstream target of ERK1/2 implicated in cell
proliferation is the serine/threonine kinase p90RSK (Fro-
din & Gammeltoft 1999). Incubation of SCLC H345 and
H146 cells with OT or VP (1 nM) induced an increase of
p90RSK phosphorylation (Fig. 4). Compared to the basal
level of p90RSK phosphorylation observed in these cells, a
1.7-fold ðn ¼ 15Þ and a 2.5-fold ðn ¼ 13Þ average p90RSK
phosphorylation increase was observed after 5 min
treatment with OT and VP respectively in H345 cells.
Similarly in H146 cells, a 2-fold ðn ¼ 6Þ and a 3-fold
ðn ¼ 6Þ average p90RSK phosphorylation increase was
observed after 5min treatment with OT and VP respec-
tively. Next, OVTA and SR49059 were used to examine
Table 2 Quantified inhibition of basal ERK1/2 and p90RSK phosphorylation after cell treatment with OT or VP antagonists. Means





Antagonist H345 cells H146 cells H345 cells H146 cells
OVTA (OTR antagonist) 28 6 (n=4) 30 7 (n=3) 249 (n=3) 266 (n=3)
SR49059 (V1aR antagonist) 41 4 (n=4) 54 8 (n=3) 387 (n=7) 3010 (n=3)
Table 3 Quantified inhibition of OT- and VP-induced ERK1/2 and p90RSK phosphorylation after cell treatment with pharmacological
inhibitors and antagonists. Means S.D. are shown
OT VP
Inhibitors H345 cells H146 cells H345 cells H146 cells
% ERK1/2 phosphorylation inhibition
OVTA (OTR antagonist) 36 8 (n=4) 305 (n=3) 7 4 (n=3) 10 2 (n=3)
SR49059 (V1aR antagonist) 20 10 (n=4) 216 (n=3) 547 (n=7) 68 10 (n=3)
U73122 (PLC inhibitor) 72 10 (n=3) 769 (n=3) 859 (n=3) 86 11 (n=3)
BAPTA-AM (Ca2+ chelator) 89 6 (n=3) 905 (n=5) 8810 (n=3) 91 11 (n=5)
GF109203X (PKC inhibitor) 63 9 (n=3) 778 (n=6) 728 (n=3) 74 6 (n=6)
U0126 (MEK1/2 inhibitor) 91 7 (n=3) 944 (n=4) 953 (n=3) 97 5 (n=4)
% 90RSK phosphorylation inhibition
OVTA (OTR antagonist) 44 12 (n=10) 586 (n=3) 257 (n=3) 26 9 (n=3)
SR49059 (V1aR antagonist) 23 12 (n=10) 125 (n=3) 5613 (n=4) 49 10 (n=3)
GF109203X (PKC inhibitor) 62 9 (n=3) 577 (n=3) 857 (n=3) 78 10 (n=3)
U0126 (MEK1/2 inhibitor) 64 12 (n=4) 608 (n=3) 8014 (n=4) 75 7 (n=3)
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the contribution of endogenous OT and VP to the basal
level of p90RSK phosphorylation observed in H345 and
H146 cells. In both SCLC cell lines, OVTA and SR49059,
used at selective concentrations of 0.5 and 10 nM
respectively, partially inhibited the p90RSK basal level of
phosphorylation in comparable proportions to what was
observed for the ERK1/2 basal level of phosphorylation
(Table 2, Fig. 4A and B). Incubation of H345 and H146
with the OTR antagonist OVTA reduced the stimulatory
effect of exogenous OT on p90RSK phosphorylation, and
to a lesser extent the effect of the exogenous VP on
p90RSK phosphorylation (Table 3, Fig. 4A). Similarly,
treatment with the V1aR antagonist SR49059 resulted in a
decrease in VP-induced p90RSK phosphorylation, while its
inhibition of OT-induced p90RSK phosphorylation was
weaker (Table 3, Fig. 4B). Moreover, the p90RSK level of
phosphorylation, resulting from the action of OVTA and
SR49059 on OT- and VP-induced p90RSK phosphoryla-
tion respectively, was under the basal level of p90RSK
phosphorylation observed in these SCLC cells (Fig. 4A
and B).
PKC inhibitor GF109203X (20 mM; Fig. 4C) and
MEK1/2 inhibitor U0126 (10mM; Fig. 4D) downregu-
lated OT- and VP-induced p90RSK phosphorylation in
both SCLC cell lines (Table 3). GF109203X and U0126
resulted in an acute decrease in VP-induced p90RSK
phosphorylation compared to the OT-induced p90RSK
phosphorylation.
Inhibition of OT- and VP-induced mitogenic
effect by acting on the OT- and VP-signalling
pathway
In order to deﬁne the signalling pathways contributing to
the OT- and VP-induced mitogenic action on SCLC
cellular growth, inhibitors described above were employed
to determine their effects on H345 and H146 [3H]thymi-
dine incorporation experiments as a measure of prolifera-
tion (Fig. 5). We have demonstrated previously that OT
and VP induce a signiﬁcant increase in H345 cell
proliferation (Pe´queux et al. 2002). Both SCLC cell lines
were therefore stimulated for 72 h with OT (1 nM) or VP
(1 nM) prior to inhibitor addition. Compared to unsti-
mulated cells, OT and VP treatments led to increases in
H345 cellular growth of 20 and 35% respectively
ðP < 0:001Þ, a range similar to that already described
(Pe´queux et al. 2002). These neuropeptides induced an
increase in H146 cell proliferation as well. Indeed, H146
cellular growth was 15 and 20% higher after OT and VP
stimulation respectively ðP < 0:001 compared with unsti-
mulated cells; Fig. 5A). After 30min inhibitor treatment,
the OT- and VP-stimulated proliferation of H345 and
H146 cells was signiﬁcantly reduced by PLC inhibitor
U73122 (2.5 mM), Ca2+ chelator BAPTA-AM (10mM),
PKC inhibitor GF109203X (10mM) and MEK1/2 inhi-
bitor U0126 (10 mM) (Fig. 5A). This effect persisted
through 4 h of exposure to the inhibitors (time, 76 h; Fig.
5C). Over 24 h of PLC inhibitor U73122 treatment (time,
96 h) cells returned to their basal growth rate and then
H345 cells remained quiescent through the 72 h incuba-
tion period while H146 cells continued to grow. The
growth rates of cells incubated with Ca2+ chelator
BAPTA-AM were 5–20% and 25–35% of basal levels
for H345 and H146 cells respectively. After 24 h of
C
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Figure 4 Effect of OT and VP on p90RSK phosphorylation with
or without pre-incubation with specific signal transduction
inhibitors. Cells were pre-incubated (þ) with OTR antagonist
OVTA (0.5 nM) (A), V1aR antagonist SR49059 (10 nM) (B) or
with solvent () for 15 min. Cells were pre-incubated (+) with
PKC inhibitor GF109203X (20mM) (C), MEK1/2 inhibitor U0126
(10mM) (D) or with solvent () for 45 min. Then, after these pre-
incubations, cells were stimulated (þ) or not () with OT (1 nM)
or VP (1 nM) for 5 min. After extraction, proteins were separated
by 10% SDS-PAGE and Western blot analysis was performed
with a polyclonal anti-phospho-p90RSK antibody. A polyclonal
anti-b-actin antibody was used to normalize loading. Western
blots shown are representative of at least three independent
experiments, each performed on H345 and H146 cells.

























































































































































































































































































■ OT, ◆ OT+U73122, ▼ OT+BAPTA-AM, ● OT+GF109203X, ▲OT+U0126
Figure 5 Effect of signalling pathway inhibitors on OT- and VP-stimulated SCLC H345 and H146 cellular growth. (A) Cellular growth
of H345 and H146 cells was estimated by [3H]thymidine incorporation when cells were stimulated with OT or VP (1 nM) for 72 h, prior
to addition of U73122 (2.5 mM), BAPTA-AM (10mM), GF109203X (10mM), U0126 (10mM) or solvent () for 30 min. For each
sample, the variation in [3H]thymidine incorporation was evaluated with respect to control unstimulated cultured H345 or H146 cells
in at least three independent experiments each performed in quadruplicate. Data are expressed as percentage variations in
[3H]thymidine ([3H]dThd) uptake (means S.D.; yP < 0:05, P < 0:001); U73122, BAPTA-AM, GF109203X or U0126 against
solvent under OT- or VP-stimulated conditions. (B) LDH measurements in supernatants of H345 and H146 cells during OT- and VP-
stimulated proliferation experiments. LDH was measured in culture medium as negative control (; left-hand bar) and in
supernatants of cells stimulated with OT or VP (1 nM) for 72 h, then added to U73122 (2.5 mM), BAPTA-AM (10mM), GF109203X
(10mM), U0126 (10mM) or solvent (, black bars) for 30 min. Positive control (þ) is LDH level obtained in supernatants when all
H345 or H146 cells are lysed. Data are expressed as LDH (ng/ml), means S.D., n ¼ 3. (C). Proliferation of OT-stimulated H345 and
H146 cells in the presence of U73122 (2.5 mM,^), BAPTA-AM (10mM,!), GF109203X (10mM,*), U0126 (10mM,~) or solvent
(&) was estimated by [3H]thymidine incorporation in at least three independent experiments each performed in quadruplicate. H345
and H146 cells were stimulated with OT (1 nM) for 72 h prior to inhibitor addition (time, 72 h). Data are expressed as [3H]thymidine
uptake (%), (means S.D.) against time (h), normalized for each sample to 100% at time 72 h; yP < 0:05, P < 0:001; U73122,
BAPTA-AM, GF109203X or U0126 against solvent under OT-stimulated conditions.
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incubation in the Ca2+ chelator (time, 96 h), both cell
lines reinitiated proliferation. PKC inhibitor GF109203X
reduced the H345 and H146 cell proliferation rate to
about 15 and 40% of the basal rate respectively, and both
cell lines remained under 40% of the basal level
throughout the exposure. In both cell lines the MEK1/2
inhibitor signiﬁcantly prevented cellular proliferation and
thus induced quiescence. This indicates that ERK1/2 is
required in the H345 and H146 cell proliferation process.
During OT- and VP-stimulated proliferation assays,
LDH measurements in supernatants of H345 and H146
cells remained at negative control level (9.5 0.8 ng/ml,
n ¼ 3) from 30 min to 72 h of exposure with various
inhibitors (Fig. 5B and results not shown). LDH values
obtained from H345 and H146 cell lysates were 56.1
1.4 ng/ml ðn ¼ 3Þ and 65.2 1.5 ng/ml ðn ¼ 3Þ respec-
tively. Altogether, these results demonstrate that signal-
ling inhibitors, used in proliferation assays, do not induce
cell lysis and therefore growth inhibitions are not a
consequence of toxicity. In addition, the absence of
toxicity was conﬁrmed by re-establishment of cell growth
after treatment (Fig. 5C). Proliferation curves obtained
for H345 and H146 cells under VP-stimulated conditions
(results not shown) were comparable to those obtained
under OT-stimulated conditions (Fig. 5C).
Discussion
Neurohypophysial peptides are involved in potent auto-
crine/paracrine signalling loops which are essential for
cellular growth processes developed by SCLC tumours
during oncogenesis (North 2000, Pe´queux et al. 2002,
Rozengurt 2002). The fact that all neurohypophysial
peptide GPCRs are expressed by SCLC cells suggest that
OT- and VP-initiated signalling is part of a complex array
of interactions culminating in the development of these
tumours (North et al. 1998b, Pe´queux et al. 2002).
Therefore, understanding the mechanistic action of such
hormones and their respective receptors in SCLC cellular
growth is essential for the development of new and
speciﬁc therapeutics.
To deﬁne the signalling pathways leading to OT- and
VP-induced mitogenic effects on SCLC, the two major
signal transduction mechanisms proposed to be associated
with the neurohypophysial peptide GPCRs (Barberis et al.
1998) were examined: (1) the inositol-mediated pathway
(which is generally associated with OTR, V1aR or V1bR/
V3R activation) leading to increases in cytosolic Ca2+
and (2) the adenylate cyclase-mediated pathway (which is
principally associated with V2R activation) leading to
increases in cAMP, and which has also been shown to be
activated by OT (Cassoni et al. 1997, 1998). By stimulat-
ing H345 SCLC cells with the OTR agonist [Thr4,
Gly7]OT and with the V1aR agonist F180 at selective
concentrations of 5 and 20 nM respectively, we have
demonstrated that the cell surface-expressed OTR and
V1aR are functional as they can mediate increases in
cytosolic Ca2+. OT-induced increases in cytosolic Ca2+
levels were found to be comparable to those observed
after VP stimulation. Since these increases could be
blocked using antagonists to OTR or V1aR, it appears
that those receptors are responsible for mediating the
majority of the OT- or VP-induced increases in cytosolic
Ca2+ levels. Additionally, we have shown that neither
OT, VP nor dDAVP (V2R agonist) was able to alter the
cAMP levels in the two SCLC cell lines H345 and H146,
under the conditions used in the following study.
Although a previous study showed that elevations in
cytosolic Ca2+ can be induced by OT (Hong & Moody
1991), they were obtained using ligand concentrations in
the range of 0.1–10 mM. The use of such high concentra-
tions raised the probability that this Ca2+ response to OT
was mediated by VP receptors. In the experiments
presented here we performed Ca2+ kinetics using 1 nM
OT, which corresponds to the order of magnitude of the
Kd value of OT towards its receptor. We also demon-
strated that the cytosolic Ca2+ elevation induced by this
level of OT was mediated principally through the OTR
and not the V1aR. First, OT was able to elicit an increase
in Ca2+ in the presence of the V1aR antagonist SR49059
(10 nM) and secondly this increase could be abolished by
the OTR antagonist OVTA (0.5 nM) thus indicating
speciﬁc activation of OTR by OT. VP has already been
demonstrated to elevate cytosolic Ca2+ in various SCLC
cell lines and particularly in H345 cells (Woll & Rozengurt
1989b, Hong & Moody 1991, Bunn et al. 1994, North et
al. 1997), but we further examined the effects of VP at the
physiological range of 1 nM and established that the Ca2+
signal induced at this concentration is largely mediated by
the V1aR. Indeed, the V1aR antagonist SR49059 (10 nM)
almost completely inhibits the Ca2+ signal, whereas
OVTA (OTR antagonist) has no measurable effect. For
the experimental conditions used here, we were not able to
demonstrate any detectable increase in cAMP, in two
different SCLC cell lines, in response to VP, dDAVP
(V2R agonist) or OT over a wide range of concentrations
(1 nM–1 mM). These data suggest that the action of VP at
V2R in H345 and H146 cells does not normally produce
an activation of the adenylate cyclase cascade. This may
be a result of the expression of an abnormally truncated
V2R form by these cells, which may block V2R function
(North et al. 1998a,b). The lack of an OT-dependent
cAMP pathway, the presence of an OT-activated Ca2+
response, and a clear mitogenic effect of OT observed on
H345 and H146 SCLC cells (Pe´queux et al. 2002 and data
shown here) is in agreement with the conclusions of
Endocrine-Related Cancer (2004) 11 871–885
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Bussolati, Cassoni and colleagues (Bussolati & Cassoni
2001, Cassoni et al. 2001). Indeed, the latter report
associated the cAMP pathway with an anti-proliferative
effect, and the Ca2+ cascade with proliferative effects.
To further identify the impact of OT and VP on the
SCLC mitogenic response, the induced phosphorylation
of ERK1/2 and p90RSK was assessed on two different
SCLC cell lines. Our results indicate that stimulation of
SCLC with exogenous OT or VP (1 nM) mediates an
increase in phosphorylation of ERK1/2 and of its
downstream target p90RSK, peaking 5min after exposure.
Since studies of Ca2+ kinetics indicated that at the
hormone concentration used there was speciﬁc activation
of OTR and V1aR, it appears that increases in ERK1/2
and p90RSK phosphorylation are also regulated by these
receptors. Moreover, the OTR antagonist OVTA and the
V1aR antagonist SR49059 reduced the basal level of
ERK1/2 and p90RSK phosphorylation in both SCLC cell
lines, demonstrating that endogenously produced OT and
VP contribute to this basal level of MAPK activation in
SCLC. Additionally, ERK1/2 and p90RSK phosphoryla-
tion induced by exogenous OT or VP was inhibited by
OVTA or SR49059 respectively, indicating that the
actions of these hormones are mediated primarily through
their corresponding receptors. It must be noted that
SCLC secretes various neuropeptides, which were shown
to activate MAPK phosphorylation as well (Rozengurt
2002). The impact of speciﬁc inhibitors of signal
transduction intermediates, tested with OT- and VP-
initiated increases of ERK1/2 phosphorylation, suggests
the involvement of PLC-, Ca2+- and PKC-dependent
pathways. Similarly, OT- and VP-induced p90RSK phos-
phorylation was PKC-dependent. Moreover, the use of
these inhibitors in [3H]thymidine-uptake assays indicates
that PLC, Ca2+, PKC and ERK1/2 are essential in the
OT- and VP-stimulated H345 and H146 SCLC cellular
growth process. Indeed, arrest of cellular growth was not
due to toxicity, but rather to blocking of mitogenic
transduction cascades.
The VP-induced phospho-ERK1/2 activation we
observed in H345 SCLC cells corroborates ﬁndings of
Seufferlein & Rozengurt (1996). However, the VP dose
they used was 100 nM. Thus, the 1 nM concentration used
in this study was chosen to dissect speciﬁc contributions
from each neurohypophysial peptide and to further
analyze the upstream pathway leading to the phosphor-
ylation of ERK1/2, as well as its downstream target
p90RSK. We demonstrated that in H345 and H146 SCLC
cells OT- and VP-induced phospho-ERK1/2 activation
was transient and PLC-, Ca2+- and PKC-dependent.
These results are in agreement with the VP-mediated
mitogenic signalling studied in rat intestinal epithelial cells
(Chiu et al. 2002) and in V1aR-transfected cells (Thibon-
nier et al. 2000), where this ERK1/2-associated pathway
could be activated simultaneously with Ca2+/calmodulin
kinase II and phosphoinositide 3-kinase cascades. The
transient OT-induced ERK1/2 phosphorylation detected
in SCLC H345 and H146 cells is in agreement with data
obtained on human uterine myometrial cells and on OTR-
transfected cells (Ohmichi et al. 1995, Strakova et al.
1998). In addition, Rimoldi et al. (2003) showed that an
OT-induced mitogenic effect, related to OTR located in
caveolin-enriched microdomains, was indeed mediated
through transient activation, whereas an OT-induced
anti-proliferative effect was associated with sustained
ERK1/2 phosphorylation. The PLC inhibitor U73122
was shown to prevent the growth of OTR-transfected
HEK293 cells; however, it did not inhibit the growth of
HEK-293 cells that expressed an OTR–caveolin 2
construct, which had the effect of localizing the OTR to
caveolin-enriched microdomains (Rimoldi et al. 2003). In
H345 and H146 SCLC cells, we observed that PLC
inhibitor U73122 abolished phospho-ERK1/2 activation
and cellular growth, which indicates that H345 and H146
cellular growth is dependent on PLC-mediated signalling
and that OTR may not be associated with caveolin-
enriched surface invaginations of these cells. Combine this
with the facts that OT induced cytosolic Ca2+ increase
and that Ca2+ is absolutely required for OT-stimulated
SCLC proliferation, the PLC-dependent OT-induced
cellular growth pathway demonstrated in this study
supports the coupling of OTR to Gaq/11, when Gai
mediates the PLC-dependent inhibitory response of OT in
OTR-transfected HEK-293 cells (Rimoldi et al. 2003).
The downstream ERK1/2 target p90RSK is involved in the
regulation of gene expression and protein synthesis, as
well as in the cell-cycle progression through regulation of
various components of the cell-cycle machinery (Frodin &
Gammeltoft 1999, Willard & Crouch 2001). We observed
that inhibitors of PKC and MEK1/2 abolished the OT-
and VP-induced p90RSK phosphorylation and inhibited
H345 and H146 SCLC cellular growth. Similarly, the
inhibition of p90RSK was shown to abolish growth
stimulation of multicellular prostate tumour spheroids
(Sauer et al. 2001). Inhibition of PKC also exhibits anti-
tumour activity in various cancer types, in studies in vitro
and in clinical trials (Mackay & Twelves 2003). Thus our
observations are in support of factors involved in cellular
growth and differentiation transduction signalling repre-
senting potential targets for anticancer therapy.
In conclusion, we demonstrate that, under pharma-
cological and physiological levels, OT- and VP-induced
mitogenic effects on SCLC pass through the speciﬁc and
respective binding of OTR and V1aR and culminate in the
activation of ERK1/2 and p90RSK phosphorylation
through PLC-, Ca2+-, PKC- and MEK1/2-dependent
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pathways (Fig. 6). Moreover, we demonstrate that growth
of OT- and VP-stimulated SCLC could be downregulated
by signalling inhibitors and was not a consequence of
toxicity. Thus the results identify pathways activated by
OT- and VP-mitogenic action on SCLC and show that
blocking of their receptor signalling represents viable
pharmacological targets for the treatment of neuroendo-
crine tumours expressing autocrine/paracrine neurohypo-
physial system loops, such as SCLC.
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